Evidence map›Paper›PMID 35442145›Full record

ArticleRNA biology2022

LINC00857 regulated by ZNF460 enhances the expression of CLDN12 by sponging miR-150-5p and recruiting SRSF1 for alternative splicing to promote epithelial-mesenchymal transformation of pancreatic adenocarcinoma cells.

Yong Zhang, Yuan Fang, Lijie Ma, Jing Xu, Chentao Lv, Li Deng, Guanghui Zhu

Open access · goldAbstract read
In one paragraph

Article in RNA biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Claudin and pancreatic cancer.Frontiers in oncology · 2023
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yong ZhangDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yuan FangDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Lijie MaDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Jing XuDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Chentao LvDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Li DengDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Guanghui ZhuDepartment of General Surgery, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Shanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent research unveiled that LINC00857 plays a regulatory role in multiple human cancers, such as lung adenocarcinoma and gastric cancer. Nevertheless, the function of LINC00857 in pancreatic adenocarcinoma (PAAD) remains unclear. This study concentrates on LINC00857 to discuss the relevant molecular mechanism of this gene in PAAD. Quantitative reverse transcription polymerase chain reaction (RT-qPCR) and western blot were implemented for measuring the expressions of RNAs and proteins. Wound healing and Transwell assays were used to assess cell migration and invasion, and fluorescent in situ hybridization (FISH) to locate LINC00857 in PAAD cells. Additionally, mechanism assays were conducted to validate the interaction between genes. Results indicated that LINC00857 was upregulated in PAAD cells and the knockdown of LINC00857 impeded PAAD cell migration, invasion and epithelial-mesenchymal transition (EMT). Further, it was found that LNC00857 regulates CLDN12 expression by targeting miR-150-5p. Moreover, LINC00857 was confirmed to recruit serine/arginine-rich splicing factor 1 (SRSF1) to promote the alternative splicing (AS) targeting CLDN12, affecting the phenotypes of PAAD cells. In addition, the transcription factor ZNF460 was proven to positively regulate LINC00857 expression. To sum up, LINC00857 regulated by ZNF460 upregulates CLDN12 expression by sponging miR-150-5p and recruiting SRSF1 to facilitate the progression of PAAD cells.[Figure: see text].

Indexed as

AdenocarcinomaAlternative SplicingEpithelial-Mesenchymal TransitionMicroRNAsPancreatic NeoplasmsRNA, Long NoncodingCell Line, TumorCell MovementCell ProliferationClaudinsDNA-Binding ProteinsHumansIn Situ Hybridization, FluorescenceSerine-Arginine Splicing FactorsTranscription FactorsClaudinsCLDN12 protein, humanDNA-Binding ProteinsLINC00857 lnc, humanMicroRNAsMIR150, humanRNA, Long NoncodingSerine-Arginine Splicing FactorsSRSF1 protein, humanTranscription FactorsZNF460 protein, humanalternative splicingCLDN12LINC00857pancreatic adenocarcinomaSRSF1transcription factor

Identifiers

PMID35442145
PMCPMC9037484
OpenAlexW4224306728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.